19 results
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with everolimus in patients with metastatic RCC. 89Zr-bevacizumab PET imaging will be regarded a promising…
The primary objective is to determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans. Secondary objectives are to explore if 89Zr-bevacizumab PET imaging can differentiate progressive from non-…
In the present study, we aim to perform a feasibility study to prove that 89Zirconium-bevacizumab PET scanning can indeed detect all small primary breast cancer lesions. Data from the present study may be used to design further studies with regard…
The main objective of the study is to determine the albuminuria lowering effect of the GLP1-RA exenetide, SGLT-2 inhibitor dapagliflozin and their combination in patients with type 2 diabetes and micro- or macroalbuminuria.Secondary objectives are…
The primary objective is to assess in a 2x2 crossover design, whether compared to placebo dapagliflozin 10 mg od for 13 weeks improves LV distensibility, measured with echocardiography in patients with early HFpEF (LVEF >= 50%), defined as…
Primary objective:To investigate the separate and combined actions of the SGLT2 inhibitor dapagliflozin and GLP-1 receptor agonist exenatide on activity in central reward and satiety circuits in response to food related stimuli in obese patients…
Primary objective: to investigate the effect of treatment with the SGLT-2 inhibitor dapagliflozin on the awareness of and counterregulatory hormone responses to hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia.…
To assess the albuminuria lowering effects of dapagliflozin in subjects with and without diabetes or hypertension and persistent elevated albuminuria.
To test our hypothesis that:The combination of the two long-acting bronchodilators indacaterol and glycopyrronium confers a superior improvement compared to nebulisation with ipratropium/salbutamol, as administered single dose in patients with…
ObjectivesPrimary objectiveThe primary objective is to determine the effect of dapagliflozin relative to placebo oncardiovascular outcomes when added to current background therapy in patients with type 2diabetes mellitus (T2DM) with either…
To explore the inflammatory changes of dapagliflozin compared with placebo on postprandial lipemia and postprandial leukocyte activation, oxidative stress and endothelial function in men with type 2 diabetes mellitus using insulin.
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…
The purpose of this study is to investigate the effectiveness and safety of dapagliflozin for glucose control in patients with exacerbation COPD on high dose glucocorticoids.Effectiveness of glucose control in clinical practice is measured by the…
The aim of this feasibility study is to validate pre-treatment [89Zr]-bevacizumab PET/CT as an imaging biomarker for prediction of treatment response to bevacizumab treatment in patients with NF2 related (vestibular) schwannomas.
Primary objective: To evaluate the effect of SGLT2 inhibition with dapagliflozin 10 mg on serum magnesium in diabetic and non-diabetic ADTKD-HNF1β patients with renal hypomagnesemia.Secondary objectives: - To evaluate the effect of SGLT2 inhibition…
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Primary: To determine the individual response to the SGTL2 inhibitor dapagliflozin in urine albumin-to-creatinine ratio (UACR) Secondary:- To determine the individual response to the SGLT2 inhibitor dapagliflozin in: - Systolic blood pressure - Body…
To investigate the potential of preoperative initiation and perioperative continuation until day 2 after surgery of the SGLT2 inhibitor dapagliflozin 10 mg once daily to prevent AKI according to the KDIGO criteria in patients undergoing…
To determine whether dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of kidney failure, hospitalization for heart failure, and all-cause mortality in the overall patient group, consisting of patients…